Document Detail

Tumoural portal vein thrombosis. Enhancement with MnDPDP.
MedLine Citation:
PMID:  9245960     Owner:  NLM     Status:  MEDLINE    
PURPOSE: Intrahepatic thrombus is usually associated with either cirrhosis or hepatocellular carcinoma (HCC). Most HCCs enhance after the administration of MnDPDP (Teslascan). Our objective was to analyze the enhancement characteristics of tumour portal vein thrombi. MATERIAL AND METHODS: Thrombi affecting the main or segmental portal veins (17 cases) and the suprahepatic inferior vena cava (1 case) were retrospectively selected from a series of 128 patients studied with MR imaging before and after the administration of MnDPDP. Enhancement was assessed qualitatively and quantitatively. RESULTS: All tumour thrombi enhanced after MnDPDP administration. The enhancement was more conspicuous in the GRE images. On the quantitative evaluation, the portal thrombus enhancement was greater for GRE images than SE images. Portal thrombi enhanced more than the liver and the HCCs. There was a significant difference between the enhancement of the HCCs and the thrombi with both MR imaging techniques. CONCLUSION: The greater enhancement of the tumour thrombus associated with the liver and HCC may suggest that other mechanisms, apart from accumulation of the contrast medium within the hepatocytes inside the thrombi, are involved in thrombus enhancement.
L Marti-Bonmati; E Lonjedo; D Mathieu; C Coffin; C Poyatos; M C Anglade
Publication Detail:
Type:  Clinical Trial; Clinical Trial, Phase III; Journal Article    
Journal Detail:
Title:  Acta radiologica (Stockholm, Sweden : 1987)     Volume:  38     ISSN:  0284-1851     ISO Abbreviation:  Acta Radiol     Publication Date:  1997 Jul 
Date Detail:
Created Date:  1997-08-28     Completed Date:  1997-08-28     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  8706123     Medline TA:  Acta Radiol     Country:  DENMARK    
Other Details:
Languages:  eng     Pagination:  655-9     Citation Subset:  IM    
Department of Radiology, Dr. Peset Hospital, Valencia, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Carcinoma, Hepatocellular / complications,  diagnosis
Contrast Media*
Edetic Acid / analogs & derivatives*,  diagnostic use
Liver Cirrhosis / complications,  diagnosis
Liver Neoplasms / complications,  diagnosis
Magnetic Resonance Imaging / instrumentation,  methods*
Manganese / diagnostic use*
Middle Aged
Neoplastic Cells, Circulating / pathology*
Portal Vein / pathology*
Pyridoxal Phosphate / analogs & derivatives*,  diagnostic use
Thrombosis / diagnosis*,  etiology
Reg. No./Substance:
0/Contrast Media; 119797-12-5/N,N'-bis(pyridoxal-5-phosphate)ethylenediamine-N,N'-diacetic acid; 54-47-7/Pyridoxal Phosphate; 60-00-4/Edetic Acid; 7439-96-5/Manganese

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  MnDPDP-enhanced MR imaging of the liver. Correlation with surgical findings.
Next Document:  Overview of MnDPDP as a pancreas-specific contrast agent for MR imaging.